Shanaya’s ex-boyfriend and filmmaker (Emraan Hashmi) is directing the film starring Sanjana. He notices Sanjana’s distress and investigates. Eventually, Aditya realizes that Shanaya is responsible. He confronts her, and Shanaya admits her insecurity: “I built this industry, and now it calls me ‘expired.’” Aditya tries to break the black magic, but the Tantrik warns that the spell is now a living entity that feeds on Shanaya’s hatred.
A flawed but fascinating hybrid of supernatural horror and industry satire, anchored by a career-defining performance. Raaz 3
Raaz 3 is the third installment in the Raaz film series (following Raaz 2002 and Raaz – The Mystery Continues 2009), which itself was inspired by the Hollywood film What Lies Beneath (2000) and the Grudge franchise. Unlike its predecessors, Raaz 3 shifts from pure paranormal horror to a meta-narrative—using black magic as a metaphor for jealousy, insecurity, and the ruthless mechanics of the film industry. He confronts her, and Shanaya admits her insecurity:
In the climax, the malevolent force turns on Shanaya herself. Sanjana (possessed by the spirit) battles Shanaya. Aditya performs a counter-ritual, and Shanaya sacrifices herself to save Sanjana, burning in the mirror’s flames. The final scene shows Aditya and Sanjana mourning, but the mirror remains—implying the evil is dormant, not destroyed. A. The Horror of Vanity & Obsolescence Unlike typical Bollywood horror focused on vengeful spirits, Raaz 3 uses supernatural events as a metaphor for professional jealousy. Shanaya’s villainy is tragic—she isn’t purely evil but deeply wounded by an industry that discards older women. Her line, “I don’t want to be a mother or a sister on screen. I want to be the heroine,” became a talking point about ageism in Hindi cinema. B. The Industry Eating Itself The film is a meta-commentary on Bollywood itself. Vikram Bhatt and Mahesh Bhatt (real-life filmmakers) portray a ruthless system where actresses are commodities. The casting of Bipasha Basu—then in her 30s and facing similar industry pressures—adds autobiographical weight. Esha Gupta, a newcomer at the time, played a version of the “threat” Basu faced in real life. C. Black Magic as Addiction The film argues that once you use black magic, it consumes you. Shanaya doesn’t just harm Sanjana; she loses her soul. This mirrors addiction or the corrupting nature of desperate ambition. 4. Horror Elements & Technical Craft | Element | Execution | |--------|-----------| | Visual Style | Dark, desaturated palette; Gothic mansion interiors; extensive use of mirrors, candlelit rituals, and fog. | | Creature Design | The spirit appears as a black smoky entity, a charred woman, and a child—reminiscent of The Ring and Grudge . | | Jump Scares | Standard but effective: lights flickering, mirrors cracking, sudden apparitions behind characters. | | Sound Design | M.M. Kreem’s background score uses low-frequency drones, sharp string stabs, and distorted lullabies. | Unlike its predecessors, Raaz 3 shifts from pure
The film was a commercial success, grossing over ₹95 crore worldwide, and is notable for Bipasha Basu’s acclaimed performance and its bold commentary on ageism and female rivalry in Bollywood. The film opens with a Tantrik (Shayaji Shinde) performing a black magic ritual that binds a malevolent spirit to an ancient mirror. That mirror ends up in the mansion of Shanaya (Bipasha Basu), a once-superstar actress now struggling to get lead roles as younger actresses rise.
Shanaya loses the lead role in a big-budget film to the younger, more popular (Esha Gupta). Consumed by jealousy, Shanaya seeks the help of the same Tantrik, who gives her a black magic totem. Using it, Shanaya begins to cause Sanjana physical and psychological harm—first accidents, then terrifying supernatural attacks.
1. Overview & Context Release Date: September 7, 2012 Director: Vikram Bhatt Producer: Mahesh Bhatt (under Vishesh Films) Music: Jeet Gannguli (songs), M.M. Kreem (background score) Cast: Bipasha Basu, Emraan Hashmi, Esha Gupta, Jacqueline Fernandez (special appearance)
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.
Outside of our clinical trials, we may provide physician-requested expanded access to its investigational products under limited situations. This is initiated when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient, which is different from a clinical trial where more comprehensive safety and efficacy data are collected. At Genelux, we recognize and understand the need for an early/expanded access policy for patients who have serious or immediately life-threatening disease and have limited available treatment options.
The request for access to a Genelux investigational drug will be considered only if the patient is an eligible patient, meaning:
In addition, prior to setting up an expanded access program or granting a request from an eligible patient’s physician, Genelux will consider whether:
At this time, based on these factors, Genelux believes that participation in one of our clinical trials is the only appropriate way to access our investigational therapies.
If the investigational drug is approved by a regulatory agency for commercial use, including provisional approval, existing expanded access programs will be phased out or modified accordingly.
Patients interested in seeking an expanded access to a Genelux investigative drug should talk to their physician. All requests must be made by the patient’s treating physician by email at . We will, in general, acknowledge receipt of a request for expanded access within five business days. We may ask for more detailed information to fully evaluate a request.
The request for access to an investigative drug can only be considered if the requesting physician agrees to obtain applicable regulatory and ethics committee approvals. We may deny access if the treating physician cannot guarantee an appropriate storage and handling of the investigative drug, which typically requires a temperature controlled deep freezer and follows Biosafety Level 2 safety procedures and precautions. The treating physician must agree to comply with regulatory obligations, including safety monitoring and reporting.
For more information on expanded access from the FDA, click here.